Skip to Content
Profiles in generosity

Don Shobrys ’75 and Carol Aronson

Concord, Massachusetts
June 27, 2017

Years after graduating from MIT, Don Shobrys, an engineer and a consultant, agreed to serve on the Annual Fund Board. The experience, he says, got him “hooked.” Since then, he has volunteered extensively at MIT. His service includes stints on the Athletics Visiting Committee and the Corporation, as president of the Alumni Association, and as co-director of the Venture Mentoring Service, which he found particularly rewarding. 

Shobrys and his wife, Carol Aronson, a process control expert, also contribute financially to MIT, focusing on the Koch Institute for Integrative Cancer Research. Both say they’ve thrived in environments of interdisciplinary collaboration in their careers, and they value this trait in the Koch Institute.

“The Koch is a microcosm of MIT in that you’ve got all kinds of disciplines working toward a common goal of cutting-­edge cancer research. I think MIT does a better job than most institutions in being able to actually move forward on interdisciplinary initiatives,” Aronson says. “Cancer requires this type of approach.”

Shobrys and Aronson have set up a charitable remainder unitrust at MIT and designated their funds for the unrestricted use of the Koch Institute. “We wanted to help provide a predictable, sustainable future source of revenue,” Shobrys says. “That’s important if you are going to innovate and evolve.”

Please consider your own gift to MIT.
For information, contact Amy Goldman:
617-715-2932; goldmana@mit.edu.
Or visit giving.mit.edu.

 

Keep Reading

Most Popular

This startup wants to copy you into an embryo for organ harvesting

With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.

VR is as good as psychedelics at helping people reach transcendence

On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.